The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 01, 2022

Filed:

Aug. 12, 2020
Applicants:

I-mab Biopharma Us Limited, Gaithersburg, MD (US);

Abl Bio Inc., Seongnam-Si, KR;

Inventors:

Wenqing Jiang, Shanghai, CN;

Lei Fang, Shanghai, CN;

Zhengyi Wang, Shanghai, CN;

Bingshi Guo, Shanghai, CN;

Eunyoung Park, Seongnam-Si, KR;

Eunsil Sung, Seongnam-Si, KR;

Byungje Sung, Seongnam-Si, KR;

Assignees:

I-Mab Biopharma US Limited, Gaithersburg, MD (US);

ABL Bio Inc., Seongnam-Si, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61P 35/00 (2018.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01);
Abstract

Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.


Find Patent Forward Citations

Loading…